Browse Internal Medicine Articles by Topic

Who Benefits from Primary Prevention ICDs?

Long-term follow-up of SCD-HeFT did not show any benefit in installing implantable cardioverter-defibrillator devices in patients with New York Heart Association class III symptoms or nonischemic cardiomyopathy.

Valve-in-Valve TAVR for Failed Surgical Prostheses: Short-Term Advantages, Long-Term Unknowns

This large retrospective study of patients undergoing reintervention for failed bioprosthetic aortic valves showed better short-term outcomes with valve-in-valve transcatheter aortic valve replacement vs. redo surgical aortic valve replacement.

Antibiotic Stewardship: Who’s Responsible?

A joint Pew/AMA survey about resistance and prescribing habits sheds light on provider attitudes and the work ahead.

High Lateral Infarction, or Something Else?

The ECG in the figure was obtained from a man with new onset palpitations. What is the probable cause of his symptoms? Is there high lateral infarction, or is something else accounting for the Q waves in leads I and aVL?

Fostemsavir Extended-Release Tablets (Rukobia)

Fostemsavir is indicated, with other antiretrovirals, to treat HIV-1 infections in heavily treatment-experienced adults with multidrug-resistant HIV-1 infections who are failing current regimens.

COVID-19 and Steroids: Is There a Consensus?

A study of adults admitted with COVID-19 pneumonia revealed risk factors associated with developing acute respiratory distress syndrome (ARDS) and progression from ARDS to death included older age, neutrophilia, organ dysfunction, and coagulation derangement.

Inappropriately Broad Empiric Antibiotics, Higher Mortality, and Community-Onset Sepsis

A retrospective cohort study revealed broad-spectrum antibiotics were unnecessarily prescribed to patients with community-onset sepsis and were associated with worse outcomes and higher mortality.

Thin Evidence Supporting the Obesity Paradox in STEMI

This largest-to-date analysis of six randomized studies of ST-elevation myocardial infarction revealed no association between body mass index and infarct size, one-year mortality, or heart failure hospitalization.

We’d Love to Hear from You!

Please complete our annual reader survey (https://bit.ly/2XYHWdM).

Ticagrelor Added to Aspirin Reduces Long-Term Risk of Recurrent Stroke or Death After Ischemic Stroke or TIAs

The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) study was designed to test the hypothesis that 30-day treatment with ticagrelor and aspirin would be superior to aspirin alone in reducing the risk of subsequent stroke or death in patients who had a non-cardioembolic ischemic stroke or transient ischemic attack.